1. Home
  2. ONTO vs VTRS Comparison

ONTO vs VTRS Comparison

Compare ONTO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onto Innovation Inc.

ONTO

Onto Innovation Inc.

HOLD

Current Price

$308.30

Market Cap

16.0B

Sector

Industrials

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$16.43

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONTO
VTRS
Founded
1940
1961
Country
United States
United States
Employees
N/A
30000
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0B
18.7B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
ONTO
VTRS
Price
$308.30
$16.43
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$290.63
$13.50
AVG Volume (30 Days)
1.1M
9.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
3.21%
EPS Growth
N/A
N/A
EPS
1.88
0.05
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$26.63
$4.41
Revenue Next Year
$16.26
$1.96
P/E Ratio
$401.04
$108.60
Revenue Growth
N/A
N/A
52 Week Low
$101.00
$9.43
52 Week High
$386.46
$18.39

Technical Indicators

Market Signals
Indicator
ONTO
VTRS
Relative Strength Index (RSI) 46.81 39.85
Support Level $240.31 $15.99
Resistance Level $309.78 $16.54
Average True Range (ATR) 19.06 0.57
MACD 0.87 -0.10
Stochastic Oscillator 60.55 3.23

Price Performance

Historical Comparison
ONTO
VTRS

About ONTO Onto Innovation Inc.

Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: